Minakem Header W48

Minakem Header W48

X

[{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine, COVID-19 Preventive Vaccine, GX-19, clinical 1\/2 Phase Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Genexine"},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine Expected to Apply for Approval of Covid-19 Vaccine Next Fall","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Genexine"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax, SK bioscience Collaborate for COVID-19 Vax Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI and SK Bioscience Extend Collaboration to Develop \u2018Next Generation\u2019 Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$26.7 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI and SK Bioscience Expand Partnership to Develop Vaccine Against Covid-19 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$210.1 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI and SK Bioscience Expand Partnership to Advance Multiple COVID-19 Variant Vaccines and Scale-Up Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK and SK bioscience's COVID Vaccine Submitted for S.Korea Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Korea Institute of Science and Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EuBiologics: Phase III Clinical Trial IND Approval of EuCorVac-19, COVID-19 Vaccine Candidate, in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"EuBiologics"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Genexine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"S.Korea's Genexine Signs COVID-19 Vaccine Candidate Manufacturing Deal with Hanmi","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Hanmi Pharmaceutical"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

SK Bioscience

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

GSK and SK bioscience's COVID Vaccine Submitted for S.Korea Approval

Details:

Protein-based SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 ‘GBP510’ with GSK pandemic adjuvant demonstrates superior neutralising titres compared to a control vaccine and clinically favourable safety profile.

Lead Product(s): GBP510

Therapeutic Area: Infections and Infectious Diseases Product Name: SKYCovione

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: GSK

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 29, 2022

ASK
US

Upload
your Pipeline Activity

EuBiologics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

EuBiologics: Phase III Clinical Trial IND Approval of EuCorVac-19, COVID-19 Vaccine Candidate, in South Korea

Details:

Eubiologics is developing EuCorVac-19, its vaccine platform, which consists of owned antigen, EulMT in-licensed from Korea Institute of Science and Technology and SNAP technology of POP Biotechnologies that EuBiologics has invested.

Lead Product(s): EuCorVac-19

Therapeutic Area: Infections and Infectious Diseases Product Name: EuCorVac-19

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Korea Institute of Science and Technology

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2022

ASK
US

Upload
your Pipeline Activity

SK Bioscience

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CEPI and SK Bioscience Expand Partnership to Advance Multiple COVID-19 Variant Vaccines and Scale-Up Manufacturing

Details:

Funding will support Phase 3 trials of SK bioscience’s recombinant protein vaccine candidate (GBP510) and adaptation for use against multiple variants of concern.

Lead Product(s): GBP510

Therapeutic Area: Infections and Infectious Diseases Product Name: GBP510

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: CEPI

Deal Size: $210.1 million Upfront Cash: Undisclosed

Deal Type: Funding May 24, 2021

ASK
US

Upload
your Pipeline Activity

Hanmi Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

S.Korea's Genexine Signs COVID-19 Vaccine Candidate Manufacturing Deal with Hanmi

Details:

Genexine 's GX-19N COVID-19 vaccine candidate is a DNA based vaccine and showed no severe side effects. Hanmi will begin producing 10M doses of Genexine’s experimental COVID-19 vaccine with an aim to gradually ramp up production capacity to millions of doses by 2022.

Lead Product(s): GX-19N

Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19N

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Genexine

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 18, 2021

ASK
US

Upload
your Pipeline Activity

SK Bioscience

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CEPI and SK Bioscience Expand Partnership to Develop Vaccine Against Covid-19 Variants

Details:

CEPI will provide up to $14.2 million to support the adaptation of SK bioscience’s recombinant protein vaccine candidate (GBP510) for use against “variants of concern”, such as the B.1.351 variant first identified in South Africa.

Lead Product(s): GBP510

Therapeutic Area: Infections and Infectious Diseases Product Name: GBP510

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: CEPI

Deal Size: $26.7 million Upfront Cash: Undisclosed

Deal Type: Funding March 10, 2021

ASK
US

Upload
your Pipeline Activity

SK Bioscience

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CEPI and SK Bioscience Extend Collaboration to Develop ‘Next Generation’ Covid-19 Vaccine

Details:

CEPI will contribute up to $10 million towards the cost of a phase I/II study of a recombinant protein vaccine candidate (GBP510)—manufactured using a nanoparticle platform—and manufacture of clinical trial materials needed for phase I/II and phase III trials.

Lead Product(s): GBP510

Therapeutic Area: Infections and Infectious Diseases Product Name: GBP510

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: CEPI

Deal Size: $10.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration December 09, 2020

ASK
US

Upload
your Pipeline Activity

Genexine

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Genexine Expected to Apply for Approval of Covid-19 Vaccine Next Fall

Details:

Genexine expects to obtain full data from a Phase I trial of its DNA vaccine GX-19 late this year or early next year, while starting a Phase IIa study within this year and concurrent Phase IIb and III trials in the first half of next year.

Lead Product(s): GX-19

Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 15, 2020

ASK
US

Upload
your Pipeline Activity

SK Bioscience

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novavax, SK bioscience Collaborate for COVID-19 Vax Candidate

Details:

SK bioscience will manufacture the vaccine antigen component for use in the final drug product globally during the pandemic period. NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2.

Lead Product(s): NVX-COV2373,Matrix-M

Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Novavax

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 13, 2020

ASK
US

Upload
your Pipeline Activity

Genexine

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Genexine, COVID-19 Preventive Vaccine, GX-19, clinical 1/2 Phase Approval

Details:

First domestic pharmaceutical company to have been approved for clinical phase 1/2a of GX-19, which is a DNA vaccine against COVID-19, by the Ministry of Food and Drug Safety.

Lead Product(s): GX-19

Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY